1 |
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30:1073-81.
DOI
|
2 |
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017;390:555-66.
DOI
|
3 |
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21.
DOI
|
4 |
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190-6.
DOI
|
5 |
Carty MJ, Pribaz JJ, Antin JH, Volpicelli ER, Toomey CE, Farkash EA, et al. A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. Plast Reconstr Surg 2011;128:112e-118e.
DOI
|
6 |
Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol 2014;32:114-20.
|
7 |
Loch-Wilkinson A, Beath KJ, Knight RJ, Wessels WL, Magnusson M, Papadopoulos T, et al. Breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand: high-surface-area textured implants are associated with increased risk. Plast Reconstr Surg 2017;140:645-54.
DOI
|
8 |
Brody GS, Deapen D, Taylor CR, Pinter-Brown L, House-Lightner SR, Andersen JS, et al. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg 2015;135:695-705.
DOI
|
9 |
Magnusson M, Beath K, Cooter R, Locke M, Prince HM, Elder E, et al. The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breastimplants. Plast Reconstr Surg 2019;143:1285-92.
DOI
|
10 |
Santanelli di Pompeo F, Sorotos M. EURAPS editorial: BIA-ALCL, a brief overview. J Plast Reconstr Aesthet Surg 2018;71:785-7.
DOI
|
11 |
Giot JP, Paek LS, Nizard N, El-Diwany M, Gaboury LA, Nelea M, et al. The double capsules in macro-textured breast implants. Biomaterials 2015;67:65-72.
DOI
|
12 |
Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol 2015;33:3750-8.
DOI
|
13 |
Kricheldorff J, Fallenberg EM, Solbach C, Gerber-Schafer C, Rancso C, Fritschen UV. Breast implant-associated lymphoma. Dtsch Arztebl Int 2018;115:628-35.
|
14 |
Hu H, Jacombs A, Vickery K, Merten SL, Pennington DG, Deva AK. Chronic biofilm infection in breast implants is associated with an increased T-cell lymphocytic infiltrate: implications for breast implant-associated lymphoma. Plast Reconstr Surg 2015;135:319-29.
DOI
|
15 |
Tardio JC, Granados R. Axillary lymphadenopathy: an outstanding presentation for breast implant-associated ALK-negative anaplastic large cell lymphoma. Int J Surg Pathol 2015;23:424-8.
DOI
|
16 |
Ebner PJ, Liu A, Gould DJ, Patel KM. Breast implant-associated anaplastic large cell lymphoma, a systematic review and indepth evaluation of the current understanding. J Surg Oncol 2019;120:573-7.
DOI
|
17 |
Leberfinger AN, Behar BJ, Williams NC, Rakszawski KL, Potochny JD, Mackay DR, et al. Breast implant-associated anaplastic large cell lymphoma: a systematic review. JAMA Surg 2017;152:1161-8.
DOI
|
18 |
Clemens MW, Horwitz SM. NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma. Aesthet Surg J 2017;37:285-9.
DOI
|
19 |
Wohlgemuth FB, Brasil MB, d'Acampora AJ. Risk of breast implant-associated anaplastic large cell lymphoma in patients submitted to breast implantation: a systematic review. Breast J 2019;25:932-7.
DOI
|
20 |
Center for Devices and Radiological Health (CDRH). Anaplastic large cell lymphoma (ALCL) in women with breast implants: preliminary FDA findings and analyses [Internet]. Silver Spring (MD): CDRH; 2011 [cited 2020 May 15]. https://www.nvpc.nl/uploads/stand/NVPC110126DOC-FN-ASPS_Final_ALCL_White_Paper_Clean_Version_1-18-1177.pdf.
|
21 |
Doren EL, Miranda RN, Selber JC, Garvey PB, Liu J, Medeiros LJ, et al. U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg 2017;139:1042-50.
DOI
|
22 |
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-90.
DOI
|
23 |
U.S. Food and Drug Adiministration (FDA). Medical device reports of breast implant-associated anaplastic large cell lymphoma [Internet]. Silver Spring (MD): FDA; 2020 [cited 2020 May 15]. https://www.fda.gov/medical-devices/breast-implants/medical-device-reports-breast-implant-associated-anaplastic-large-cell-lymphoma.
|
24 |
de Jong D, Vasmel WL, de Boer JP, Verhave G, Barbe E, Casparie MK, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA 2008;300:2030-5.
DOI
|
25 |
Wu D, Allen CT, Fromm JR. Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. Cytometry B Clin Cytom 2015;88:58-63.
DOI
|
26 |
Talagas M, Uguen A, Charles-Petillon F, Conan-Charlet V, Marion V, Hu W, et al. Breast implant-associated anaplastic large-cell lymphoma can be a diagnostic challenge for pathologists. Acta Cytol 2014;58:103-7.
DOI
|
27 |
Kim B, Predmore ZS, Mattke S, van Busum K, Gidengil CA. Breast implant-associated anaplastic large cell lymphoma: updated results from a structured expert consultation process. Plast Reconstr Surg Glob Open 2015;3:e296.
DOI
|
28 |
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-68.
DOI
|
29 |
Estes CF, Zhang D, Reyes R, Korentager R, McGinness M, Lominska C. Locally advanced breast implant-associated anaplastic large-cell lymphoma: a case report of successful treatment with radiation and chemotherapy. Front Oncol 2015;5:26.
DOI
|
30 |
Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol 2016;34:160-8.
|
31 |
Johnson L, O'Donoghue JM, McLean N, Turton P, Khan AA, Turner SD, et al. Breast implant associated anaplastic large cell lymphoma: the UK experience: recommendations on its management and implications for informed consent. Eur J Surg Oncol 2017;43:1393-401.
DOI
|
32 |
Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol 2015;33:3759-65.
DOI
|
33 |
Ministry of Food and Drug Safety; Korean Society of Plastic and Reconstructive Surgeons. The report of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in Korea [Internet]. Cheongju, KR: Ministry of Food and Drug Safety; 2019 [cited 2020 May 15]. https://www.mfds.go.kr/brd/m_99/view.do?seq=43641.
|
34 |
Gye SH. Unfinished fear for Allergan artificial breast: the third rare cancer in Korea occurs [Internet]. Seoul, KR: Yonhap News; 2020 [cited 2020 Oct 15]. https://www.yna.co.kr/view/AKR20201004030000017?input=1195m.
|
35 |
Keech JA Jr, Creech BJ. Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. Plast Reconstr Surg 1997;100:554-5.
DOI
|